Drug Profile


Alternative Names: Autologous CD34+ cells - Caladrius; CLBS-12

Latest Information Update: 22 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Caladrius Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Peripheral ischaemia

Highest Development Phases

  • Preclinical Peripheral ischaemia

Most Recent Events

  • 18 Apr 2016 CLBS 12 is available for licensing as of 18 Apr 2016.
  • 18 Apr 2016 Caladrius Biosciences announces that Japanese PMDA thirty-day review period passed without any comments from PMDA
  • 23 Jul 2015 Caladrius Biosciences plans a phase II trial for Peripheral Ischaemia in Japan (NCT02501018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top